logo
  

Wabash National Maintains FY24 Outlook; Q1 Results Miss Estimates

While reporting financial results for the first quarter on Wednesday, Wabash National Corp. (WNC) maintained its earnings outlook for the full-year 2024, as first-quarter shipment delays to flow into subsequent quarters.

For fiscal 2024, the company continues to project earnings in the range of $2.00 to $2.50 per share on revenues between about $2.2 billion and $2.4 billion.

On average, three analysts polled by Thomson Reuters expect the company to report earnings of $2.19 per share on revenues of $2.25 billion for the year. Analysts' estimates typically exclude special items.

For the first quarter, the company reported net income attributable to common stockholders of $18.17 million or $0.39 per share, sharply down from $51.21 million or $1.04 per share in the prior-year quarter.

Net sales for the quarter declined 17.0 percent to $515.28 million from $620.95 million in the same quarter last year.

The Street was looking for earnings of $0.45 per share on net sales of $516.85 million for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT